The July 2022 issue of IEEE Spectrum is here!

Close bar

Electric Jolt to the Brain Helps Stop Stutters

Weak electrical stimulation to the brain’s speech regions enhances the benefits of speech therapy for those who stutter

4 min read
Person receiving direct current stimulation
Photo: Peggy Conner/Lehman College

Their tongues might trip up over the name of the treatment, but people who stutter perform better on a speech test after receiving a daily jolt of transcranial direct current stimulation (tDCS).

That’s according to the results of a British trial, which found that coupling brain zapping with a five-day course of speech therapy helps those with stutters make positive, lasting changes in their communication skills.

Hobbyists and athletes are already using tDCS to boost their memory, learning, and creativity. And there’s a growing body of evidence that the neurostimulation can ease the symptoms of pain and depression, as well as promote recovery in stroke victims, including in their language skills.

But the new report, which will appear in the April 2018 issue of the journal Brain, is the first from a randomized clinical trial—the gold standard in medical research—to show that the technique can improve speech fluency in people who have not suffered any major insult to the brain but instead have a developmental speech condition.

“It’s a big deal,” says Rick Arenas, a speech scientist who runs the University of New Mexico Stuttering Lab and was not involved in the study. Neurostimulation, he says, “really looks extremely promising.”

Why it’s helping, however, remains unclear. It’s thought that the tDCS augments the brain’s ability to reorganize itself, thereby strengthening the new neural connections formed during behavioral speech therapy. But as Elizabeth Galletta, a speech-language pathologist at NYU Langone’s Rusk Rehabilitation, readily admits: “It’s still a black box.”

For the study, Jen Chesters, a speech and language therapist at the University of Oxford, worked with 30 stuttering speakers, spending five straight days training the men to read aloud and converse at a normal pace. (All were male to reduce variability between subjects.) During each day’s 20-minute therapy session, the participants all wore electrical caps on their heads, but only half actually received tDCS; the others received only sham stimulation—a brief buzz to trick people into thinking they were getting the real deal—and neither Chesters nor the participants knew who was getting what.

The tDCS device delivered a weak electric current through a credit card–sized electrode to the brain’s left frontal cortex, the key region for speech planning and production. The stimulation involved a constant current of just 1 milliamp—less than what’s needed to power a typical LED. Yet, that tiny tingle made all the difference.

Participants who received the tDCS showed significant reductions in their stuttering severity, both one week and six weeks after the intervention, whereas those who got the sham treatment experienced little to no change. “The tDCS is working to boost the effects of the behavioral intervention,” Chesters says.

That electric boost only helped modify certain measures of stuttering, though. It had lasting effects on participants’ abilities to declaim a written passage, but the increased conversational fluency that the men experienced one week after the intervention disappeared by week six. Outward improvements in speech smoothness also didn’t translate into improvements in the psychosocial aspects of stuttering, as measured by a self-assessment tool of participants’ own experiences.

So, while Galletta describes the Oxford team’s results as “very exciting,” she also thinks that tDCS researchers “need to look at stuttering in a more holistic way.”

Looking ahead, Chesters and her Oxford colleagues, led by neuropsychologist Kate Watkins, are planning to gather a wide range of metrics in their next study, a 40-person follow-up called INSTEP that is currently open for enrollment. In that trial, the researchers are pairing a 20-minute stimulation protocol in speech regions from both halves of the brain with a 40-minute speech-training paradigm (to be closer to a true clinical session), and then testing participants 12 weeks out from their weeklong intervention to see how long the benefits persist.

Meanwhile, across the pond at the University of Michigan in Ann Arbor, speech neurophysiologist Soo-Eun Chang and her colleagues are running their own tDCS trial for stuttering, but it differs from the Oxford group’s INSTEP study in a number of ways. It’s using high-definition tDCS, with electrodes smaller than a dime, to deliver 1.5 milliAmps of localized stimulation to a region in the brain involved in speech timing called the supplementary motor area.

Chang and her team are also putting study subjects in a brain scanner, applying functional magnetic resonance imaging before the intervention, right afterwards, and then at two later follow-up times. “The whole point is to see if we can increase their fluency level,” says Chang. “But on top of that, we are aiming to increase brain connectivity patterns with tDCS that may help sustain fluent speech for longer periods."

Given the ease with which amateur enthusiasts can now build their own tDCS rigs, there may be a temptation among people who stutter to shoot currents through their own heads as they engage in their fluency homework—but Arenas, who himself talks with a stutter and has tried tDCS for his own speech impediment, cautions against doing so. “This is extremely early on,” he says, “and there’s still a lot of work that should be done.”

Among the variables to be tested: where to place the electrodes, how much current to use, how long to deliver stimulation, and what kinds of behavioral tasks best pair with tDCS. “A lot of methodological research will be necessary to find out what the optimal parameters are, because there are a lot of choices you can make,” says Dirk den Ouden, a neurolinguist at the University of South Carolina.

Peggy Conner, a speech-language pathologist from CUNY’s Lehman College, has another concern about the technology. As she and other experts hone in on the optimal way deliver tDCS for persistent stutterers, there’s a risk that they may inadvertently further medicalize and stigmatize a condition that many think should instead be embraced as part of the normal neurodevelopmental spectrum.

“The danger of the pursuit of fluency for people who stutter,” Conner says, “is we may mitigate a greater societal need for stuttering acceptance.”

The Conversation (0)
A photo showing machinery in a lab

Foundries such as the Edinburgh Genome Foundry assemble fragments of synthetic DNA and send them to labs for testing in cells.

Edinburgh Genome Foundry, University of Edinburgh

In the next decade, medical science may finally advance cures for some of the most complex diseases that plague humanity. Many diseases are caused by mutations in the human genome, which can either be inherited from our parents (such as in cystic fibrosis), or acquired during life, such as most types of cancer. For some of these conditions, medical researchers have identified the exact mutations that lead to disease; but in many more, they're still seeking answers. And without understanding the cause of a problem, it's pretty tough to find a cure.

We believe that a key enabling technology in this quest is a computer-aided design (CAD) program for genome editing, which our organization is launching this week at the Genome Project-write (GP-write) conference.

With this CAD program, medical researchers will be able to quickly design hundreds of different genomes with any combination of mutations and send the genetic code to a company that manufactures strings of DNA. Those fragments of synthesized DNA can then be sent to a foundry for assembly, and finally to a lab where the designed genomes can be tested in cells. Based on how the cells grow, researchers can use the CAD program to iterate with a new batch of redesigned genomes, sharing data for collaborative efforts. Enabling fast redesign of thousands of variants can only be achieved through automation; at that scale, researchers just might identify the combinations of mutations that are causing genetic diseases. This is the first critical R&D step toward finding cures.

Keep Reading ↓Show less